Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease ("IBD") and rheumatic diseases. The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23, which are being developed as both monotherapies and pair-wise combinations. Spyre's strategy involves three main pillars: advancing a portfolio of next-generation monotherapies, evaluating IBD combinations, and expanding its anti-TL1A program into additional indications. The next-generation monotherapy antibody candidates, SPY001, SPY002, and SPY003, target α4β7, TL1A, and IL-23, respectively. These candidates are engineered for optimized potency, selectivity, and pharmacokinetics ("PK") against validated IBD targets. They incorporate Fc domain modifications called YTE substitutions to increase pharmacokinetic half-life and are formulated as high-concentration, citrate-free formulations. These attributes aim to enable quarterly or twice annual subcutaneous ("SC") maintenance dosing. The company is also exploring fixed-dose-combinations of its investigational antibodies. The anti-TL1A program is being expanded into additional indications, starting with rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA").